CD19 and diffuse large B-cell lymphoma: Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), lisocabtagene maraleucel (liso-cel) and brexucabtagene autoleucel (brexu-cel) are four CD19 directed CAR T cells approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of relapse or refractory (R/R) diffuse large diffuse B cell lymphoma (DLBCL), indolent lymphoma and mantle cell lymphoma (MCL) [1–6].